Boosting the immune system response
|Researcher||Dr Stephen Mattarollo|
|Institute||The University of Queensland, Diamantina Institute|
|Project title||Treating blood cancers by activating and boosting the immune system response to cancer|
|Disease focus||Non-Hodgkin lymphoma|
Dr Stephen Mattarollo is leading the vaccine development. His research team is using pre-clinical models of NHL to investigate the benefits of combining the vaccine with the front-line therapy, Rituximab, to improve patient outcomes.
According to Dr Mattarollo, the vaccine boosts the immune system by stimulating the expansion and activity of Natural Killer T cells and CD8 T cells.
“Our immune system is actually capable of killing blood cancer cells, but cancers generally suppress the immune response,” he said.
“We’ve developed a therapeutic vaccine that re-activates the immune system to help it better target and kill non-Hodgkin lymphoma cells.
“We believe our vaccine strategy may complement front-line therapies, such as Rituximab, and many chemotherapeutics that rely on components of an immune response for their effectiveness.
“Hopefully this project will provide a platform for future trials of the vaccine in patients as well as a sound rationale for combining immunotherapeutic approaches in non-Hodgkin lymphoma.”
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.